FDA Webview
X

Free FDA Notices

Panels to Discuss Avedro NDA For Ophthalmic Conditions

01/28/2015

Federal Register Notice: FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel of the Medical Devices Advisory Committee will meet 2/24, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committees will discuss an Avedro, Inc. NDA for riboflavin ophthalmic solutions with UV-A irradiation. The combination products are used in corneal collagen cross-linking and proposed to be indicated for treating progressive keratoconus or corneal ectasia following refractive surgery. Contact Moon Hee V. Choi, (301) 796-9001. To view this notice, click here.

LATEST NEWS